A Paradigm-Challenging Result in Atypical EGFR-Mutant Lung Cancer: A 41-Month Survival Signal
In this article
What Do the Amivantamab + Lazertinib Results Mean in Lung Cancer with Atypical EGFR Mutations?
Atypical EGFR Mutations Do Not Behave Like Classic EGFR Mutations
Targeted therapy in EGFR-mutant NSCLC is one of the most successful examples of molecular oncology in lung cancer practice. However, this success is most clearly established in classic sensitizing EGFR mutations, namely exon 19 deletion and L858R. Responses in atypical EGFR mutations are more variable. Some mutations may be more sensitive to second-generation EGFR TKIs, whereas others produce more limited responses; with compound mutations, the response pattern becomes even more complex.
It is therefore no longer sufficient to regard patients with atypical EGFR mutations as a uniform group under the heading “EGFR-mutant.” Treatment decisions should be individualized according to the mutation subtype, accompanying molecular alterations, presence of brain metastases, prior treatments, toxicity profile, and access to drugs.
Brief Concept Note: What Does an Atypical EGFR Mutation Mean?
An atypical EGFR mutationrefers to rarer EGFR alterations other than the classic EGFR exon 19 deletion and L858R. This group includes G719X, L861Q, S768I, E709X, some exon 18 alterations, and compound mutations. Although EGFR exon 20 insertions also belong to the rare EGFR group, they are evaluated separately in most studies because their biology and treatment approach differ.
Why Is Amivantamab + Lazertinib a Rational Combination?
Amivantamabis a bispecific antibody targeting both EGFR and MET. In other words, a single antibody molecule can bind to two different targets. EGFR signaling can be one of the main drivers of tumor growth, while the MET pathway can play an important role in resistance and escape biology.
Lazertinib is a third-generation oral EGFR tyrosine kinase inhibitor. The aim of this combination is to target the EGFR pathway both outside the cell at the antibody level and inside the cell at the TKI level, while providing broader suppression of resistance mechanisms that may develop through MET.
Brief Concept Note: What Are a Bispecific Antibody and a TKI?
A bispecific antibodyis a type of antibody that can bind to two different targets simultaneously. Amivantamab targets both EGFR and MET. TKIstands for tyrosine kinase inhibitor; it is a class of orally administered targeted drugs that suppress the enzymes transmitting growth signals within cancer cells.
Which Mutations Are We Discussing?
Atypical EGFR mutations are not a single biological group. Some mutations affect the EGFR drug-binding pocket differently; some alter the protein structure; and others occur together with other EGFR mutations. The name of the mutation therefore has direct significance for treatment decisions.
| Subgroup | Examples | Clinical significance | Importance for treatment decisions |
|---|---|---|---|
| Major atypical EGFR mutations | G719X, S768I, L861Q / L861X | TKI sensitivity varies; they should not be viewed like classic exon 19 deletion or L858R. | Options such as afatinib, osimertinib, and amivantamab-based combinations are discussed according to the mutation subtype. |
| Compound / complex EGFR mutations | G719X + S768I, G719X + L861Q, etc. | More than one EGFR alteration is present in the same tumor; the response pattern may vary according to the combination. | They should not be interpreted as a single mutation; the molecular report should be read in detail. |
| Other rare EGFR mutations | E709X, L747P/S, exon 18 alterations, etc. | They are less common; prospective data are limited. | Treatment decisions should be individualized for each patient with reference to the literature and a molecular tumor board. |
| EGFR exon 20 insertion | Ex20ins variants | In a broad sense, they belong to the rare EGFR group; however, their biology and treatment differ. | Exon 20-specific approaches, such as sunvozertinib and amivantamab + chemotherapy, are considered separately. |
The Atypical EGFR Cohort of an Open-Label Phase 1/1b Study
CHRYSALIS-2 is an open-label phase 1/1b study evaluating lazertinib alone or in combination with amivantamab in patients with advanced NSCLC. The ASCO 2026 update focused on cohort C , which includes patients with atypical EGFR mutations.
This analysis evaluated 49 patients who received first-line amivantamab + lazertinib. The cohort excluded classic EGFR exon 19 deletion, L858R, and EGFR exon 20 insertions. This distinction matters because the study directly targets atypical EGFR biology that is “nonclassic, but also not exon 20.”
Patient group
Advanced NSCLC with atypical EGFR mutations; classic exon 19 deletion, L858R, and exon 20 insertions were excluded.
Treatment
Intravenous amivantamab combined with oral lazertinib; recommended doses are amivantamab 1050 mg, or 1400 mg for ≥80 kg, and lazertinib 240 mg.
Main measures
Objective response rate, duration of response, clinical benefit rate, progression-free survival, overall survival, and safety.
| Mutation group | Representation in cohort C | Approximate proportion | Clinical interpretation |
|---|---|---|---|
| G719X | The most common atypical EGFR mutation | %55 | One of the best-known and more frequent alterations in the atypical EGFR group. |
| S768X / S768I | Another important atypical EGFR alteration | %27 | May occur alone or as part of a compound mutation. |
| L861X / L861Q | A frequently encountered major uncommon mutation | %24 | A subgroup that differs from classic EGFR mutations but may show sensitivity to targeted therapy. |
| Compound EGFR mutations | The coexistence of more than one atypical EGFR alteration | %35 | Treatment response may depend on the biological effect of the combination rather than a single mutation. |
Brief Concept Note: What Does a Compound Mutation Mean?
A compound mutationis the coexistence of more than one EGFR alteration in the same tumor. For example, combinations such as G719X + S768I or G719X + L861Q may occur. This can make treatment sensitivity more complex than with a single mutation.
Median Overall Survival of 41 Months: A Strong Signal for Atypical EGFR
In the ASCO 2026 update, the median follow-up was 31,3 months . Median overall survival in the 49 patients receiving first-line amivantamab + lazertinib was reported as 41,0 months . The 12-month OS rate was %85, the 24-month OS rate was %72, and the 36-month OS rate was %55 .
Brief Concept Note: What Are Overall Survival and Median Follow-Up?
Overall survivalrefers to the time until patients die from any cause. Median follow-upis the median duration of patient observation in the study; longer follow-up increases the reliability of survival data in particular.
Clinical Meaning of the Survival Data
- OS of 41 months: A striking long-term result in a heterogeneous and challenging group such as advanced NSCLC with atypical EGFR mutations.
- Three-year OS of 55%: More than half of patients being alive at 3 years is a strong survival signal for this subgroup.
- Single-arm data: Although the result is highly impressive, it is not a randomized comparison; it should therefore not be interpreted at the level of standard-changing phase 3 evidence.
- Real-world context: Median OS was reported as 15,2 months in a real-world cohort receiving a physician's choice of first-line EGFR TKI; however, this is not a direct comparison.
Response Rate of 57%, Clinical Benefit Rate of 84%
The combination delivered striking results not only for survival but also for tumor response. The objective response rate was reported as %57, and the clinical benefit rate as %84 . Median progression-free survival was 19,5 months, and median duration of response was 20,7 months .
Brief Concept Note: What Are ORR, CBR, PFS, and DOR?
ORRis the objective response rate; it indicates the proportion of patients whose tumors shrink measurably. CBRis the clinical benefit rate; it includes patients who respond or whose disease remains stable for a specified period. PFSmeans progression-free survival, the period during which the disease remains controlled without progression. DORmeans duration of response; it indicates how long tumor shrinkage lasts.
| Outcome | Amivantamab + Lazertinib | Clinical significance |
|---|---|---|
| Number of patients | 49 | Patients with advanced NSCLC with atypical EGFR mutations receiving first-line treatment. |
| Median follow-up | 31,3 months | A meaningful observation period for the survival data has now been reached. |
| Median overall survival | 41,0 months | A highly striking long-term survival signal in this challenging subgroup. |
| 12 / 24 / 36-month OS | %85 / %72 / %55 | The survival curve remains clinically strong over time. |
| Objective response rate | %57 | Measurable tumor shrinkage in more than half of patients. |
| Clinical benefit rate | %84 | A high rate of clinical control through response or stable disease. |
| Median PFS | 19,5 months | The period during which disease remains controlled without progression is striking. |
| Median DOR | 20,7 months | Suggests that responses may be not only frequent but also durable. |
Why Was Treatment Challenging in Atypical EGFR?
The treatment success achieved in classic EGFR mutations could not be directly replicated for atypical EGFR mutations. First-generation EGFR TKIs often proved inadequate in these mutations. Afatinib demonstrated clinical activity in some major uncommon EGFR mutations, such as G719X, L861Q, and S768I, and became an important option in this field. Although osimertinib also showed activity in some atypical mutations, results varied according to the mutation subtype and the presence of compound mutations.
The greatest problem in patients with atypical EGFR mutations is that data often come from small cohorts, retrospective series, or single-arm studies. It is therefore not easy to place every mutation subtype within the same treatment algorithm. The value of CHRYSALIS-2 cohort C is that a combination with broader mechanisms of action produced a long-term efficacy signal in this challenging patient group.
| Approach | Target / mechanism | Strength | Limitation | Relationship to CHRYSALIS-2 |
|---|---|---|---|---|
| First-generation EGFR TKIs | EGFR tyrosine kinase inhibition | Historical foundation in classic EGFR mutations | Efficacy in atypical mutations is variable and often limited | One of the early experiences demonstrating that atypical EGFR cannot be treated like classic EGFR. |
| Afatinib | Irreversible inhibitor of the ErbB family | Clinical activity in some major uncommon mutations such as G719X, S768I, and L861Q | Response and durability vary by mutation subtype; toxicity management is required | Reinforced the idea of biology-based selection in atypical EGFR treatment. |
| Osimertinib | Third-generation EGFR TKI | Of interest because of its CNS activity and strong position in classic EGFR disease | Efficacy in atypical mutations is heterogeneous; prospective data are limited | Suggests that TKI monotherapy may not be the only path in atypical EGFR. |
| Amivantamab + lazertinib | EGFR/MET bispecific antibody + third-generation EGFR TKI | Signals of ORR 57%, PFS 19,5 months, and OS 41,0 months | Single-arm phase 1/1b data; randomized validation is required | Shows that a multitarget approach may be a strong first-line candidate in atypical EGFR. |
This Table Is Not a Direct Head-to-Head Comparison
Studies in atypical EGFR involve different patient populations, mutation subtypes, and treatment lines. Data on afatinib, osimertinib, and amivantamab + lazertinib therefore do not directly answer the question “Which is better?” The appropriate interpretation is that treatment in patients with atypical EGFR mutations should be personalized according to the mutation subtype and clinical context.
How Should OS of 41 Months Be Interpreted Alongside a Real-World Cohort Receiving Physician-Selected EGFR TKIs?
To put the CHRYSALIS-2 findings into context, the researchers also evaluated a noncomparative, retrospective real-world cohort of NSCLC with atypical EGFR mutations. In this cohort, median overall survival among patients receiving a physician's choice of first-line EGFR TKI was reported as 15,2 months .
Although this difference appears very large at first glance, caution is needed. This analysis is not randomized; patient selection, treatment access, follow-up duration, mutation distribution, performance status, and subsequent treatment options may differ. Nevertheless, it provides valuable context for understanding the clinical weight of the OS result of 41,0 months.
Brief Concept Note: The Difference Between Real-World Data and a Randomized Study
Real-world dataare observational data obtained from patients treated in routine clinical practice. A randomized study is a research design in which patients are randomly assigned to treatment arms, reducing bias. Real-world data provide clinical context, but alone do not establish evidence of causality.
Truecheck Note
The difference between 41,0 months and 15,2 months should not be interpreted as a direct randomized comparison. CHRYSALIS-2 cohort C is a single-arm phase 1/1b study, whereas the real-world cohort is observational. The result should therefore be read as “there is a very strong survival signal that needs validation,” rather than “amivantamab + lazertinib is definitively superior to all TKIs.”
Expected Adverse Effects of Targeting EGFR and MET
With long follow-up, the safety profile of amivantamab + lazertinib was consistent with previous experience, and no new safety signal was reported. Most adverse effects were grade 1–2. The most common included paronychia, rash, diarrhea, stomatitis, pruritus, hypoalbuminemia, peripheral edema, and infusion reactions.
Brief Concept Note: What Are Paronychia, Hypoalbuminemia, and an Infusion Reaction?
Paronychiais inflammation around the nail characterized by pain, redness, swelling, or infection-like changes; it is common with EGFR-targeted therapies. Hypoalbuminemiais a decrease in the blood albumin level and may be associated with edema. An infusion reactionis the development of reactions such as fever, chills, shortness of breath, rash, or changes in blood pressure during intravenous drug administration.
Practical Areas of Toxicity Management
- Skin and nails: Rash and paronychia should be recognized early; topical treatments, antibiotics, and dose management may be required.
- Infusion reaction: Close monitoring and premedication are important, especially during the first amivantamab administrations.
- Edema and albumin: Peripheral edema and hypoalbuminemia may be associated with MET-targeted therapies; clinical monitoring is required.
- Gastrointestinal toxicity: Diarrhea and stomatitis should be managed early with patient education.
- Long treatment duration: Because a substantial proportion of patients could remain on treatment for 2 years or more, management of chronic toxicity becomes critical.
It Is Time to Stop Treating Atypical EGFR as a Single Category
The most important message of CHRYSALIS-2 cohort C is that atypical EGFR mutations should now be addressed in greater detail. Algorithms for classic EGFR mutations may have become clear, and separate targeted therapies are being developed for exon 20 insertions; however, decisions for G719X, L861Q, S768I, and compound mutations remain complex.
Amivantamab + lazertinib is a strong candidate for a first-line option in this patient group. However, because the data are single-arm, it would be more appropriate today to discuss it, particularly at experienced centers and molecular tumor boards, rather than present it as an automatic standard for every patient.
Points to Consider When Selecting Patients
- Mutation subtype: The presence of G719X, L861Q, S768I, or compound mutations should be reported in detail.
- Distinguishing exon 20: Exon 20 insertions were excluded from this analysis; they require a separate treatment algorithm.
- Brain metastases: Treatment selection and follow-up are particularly important with CNS involvement.
- MET pathway and resistance: Amivantamab's dual EGFR/MET targeting may offer a theoretical advantage in terms of resistance biology.
- Tolerance of toxicity: Skin and nail adverse effects, edema, and infusion reactions that may require prolonged treatment should be manageable.
- Access and authorization: The specific indication for atypical EGFR may vary according to country-specific authorization and reimbursement conditions.
How Should We Discuss This with Patients?
“If your lung cancer has a rarer EGFR alteration that differs from classic EGFR mutations, choosing treatment can be more complex. New data suggest that the combination of amivantamab and lazertinib may provide long-term disease control and survival in this specific patient group. However, these results still come from a single-arm study; when making a decision, your mutation subtype, overall condition, presence or absence of brain metastases, risk of adverse effects, and access to drugs should therefore be assessed together.”
Atypical EGFR Mutations Must Now Be Taken More Seriously
Academic Assessment
Median overall survival reaching 41 months in lung cancer with atypical EGFR mutations makes amivantamab + lazertinib a particularly striking first-line option in this challenging patient group.
These data show that we should now consider EGFR mutations not only through classic exon 19 deletion and L858R, but also recognize atypical mutations as a distinct and important biological group.
In the future, the most appropriate treatment selection for these patients will be shaped by a more personalized approach that assesses the mutation subtype, accompanying molecular alterations, and toxicity management together.
What Evidence Is Needed to Become a Standard?
Open Questions
- Randomized validation: Will amivantamab + lazertinib demonstrate superiority over afatinib, osimertinib, or a physician's choice of EGFR TKI at the phase 3 level?
- Mutation subtype: Is efficacy the same in G719X, L861Q, S768I, and compound mutations, or are there marked differences?
- CNS efficacy: How strong and lasting is the control provided by the combination in patients with atypical EGFR mutations and brain metastases?
- Resistance mechanism: Which molecular escape pathways emerge after amivantamab + lazertinib?
- Subcutaneous amivantamab: Can new formulations reduce treatment burden in terms of ease of administration and infusion reactions for patients receiving prolonged treatment?
- Real-world data: Will the results be maintained in older patients, patients with comorbidities, different ethnic groups, and different mutation combinations?
Truecheck Note
Although CHRYSALIS-2 cohort C data provide a very strong signal for survival and disease control, the study has a single-arm phase 1/1b design. Results should therefore not be directly evaluated at the level of phase 3 randomized, standard-changing evidence. Nevertheless, considering the limited treatment options in NSCLC with atypical EGFR mutations, the OS signal of 41 months is highly striking clinically.
A New First-Line Candidate Gains Strength in Atypical EGFR
The CHRYSALIS-2 cohort C update presented at ASCO 2026 shows that first-line amivantamab + lazertinib provides a strong and durable efficacy signal in advanced NSCLC with atypical EGFR mutations. In the analysis of 49 patients, median overall survival was reported as 41,0 months, the 36-month OS rate as 55%, the objective response rate as 57%, the clinical benefit rate as 84%, median PFS as 19,5 months, and median duration of response as 20,7 months.
These results show that atypical EGFR mutations should no longer be treated as a “rare but secondary” footnote, but as a separate area of biological and clinical decision-making. Classic EGFR mutations, exon 20 insertions, and atypical EGFR mutations should be distinguished, and each patient's molecular report should be interpreted in detail.
At present, amivantamab + lazertinib is a very strong candidate first-line strategy in this field; however, randomized validation, more detailed analyses by mutation subtype, CNS efficacy, and real-world data will determine its ultimate place in treatment. Even so, these data clearly show that the era of more personalized and multitarget treatment is gaining strength in lung cancer with atypical EGFR mutations.
References
- ASCO 2026 Abstract #8501. Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced NSCLC: updated results from the CHRYSALIS-2 study.
- Johnson & Johnson. RYBREVANT plus LAZCLUZE demonstrates prolonged clinical benefit as first-line treatment for atypical EGFR-mutated NSCLC. 29 May 2026.
- OncLive. Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC. 29 May 2026.
- Tomasini P et al. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. Journal of Clinical Oncology. 2026;44(1):54-65.
- PubMed. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC: CHRYSALIS-2 cohort C.
- ClinicalTrials.gov. CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced NSCLC. NCT04077463.
- The ASCO Post. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC. 2025.
- Janssen MedicalConnect. Use of RYBREVANT in metastatic NSCLC with atypical or uncommon EGFR mutations.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.